3342-78-7Relevant articles and documents
Modification of substrate reactivity using soluble polymeric supports
Bergbreiter, David E.
, p. 4757 - 4760 (1995)
The effects of polymer size and solvent on the reactivity of a soluble polymer-bound substrate in heterogeneous hydrogenation reactions has been examined using PEG polymer ligands. Hydrogenation of a substrate was completely suppressed by virtue of the po
Textile-supported silver nanoparticles as a highly efficient and recyclable heterogeneous catalyst for nitroaromatic reduction at room temperature
Feng, Wei,Huang, Tingting,Gao, Liqian,Yang, Xianfeng,Deng, Wenbin,Zhou, Rui,Liu, Hongjun
, p. 6288 - 6292 (2018/02/19)
A novel textile-based nanosilver catalyst was prepared with a facile synthetic method. The textile-supported nanosilver (TsNS) proved to be an excellent heterogeneous catalyst for the reduction of nitroaromatics with a broad substrate scope. It can be recycled for up to 6 times without significantly compromising its catalytic efficacy. The TsNS catalyst was developed into a column reactor, demonstrating its practical application with the advantages of low cost, ease of operation and large scale synthesis capabilities. Scanning electron microscopy (SEM) showed that there were few changes to the catalyst's surface after the reaction. Besides, inductively coupled plasma (ICP) analysis showed that few silver particles leaked, and the interactions between the nitro groups of the nitroaromatics and the nanosilver particles were characterized by X-ray photoelectron spectroscopy (XPS), which lead to the proposal of a four-step mechanism for the reduction reaction.
NOVEL COMPOUNDS
-
Page/Page column 27, (2012/03/26)
Novel retinoid-related orphan receptor gamma (ROR?) modulators and their use in the treatment of diseases mediated by ROR? provided by the present invention.
TARGETING DIAZO PRODRUGS FOR THE TREATMENT OF GASTROINTESTINAL DISEASES
-
Page/Page column 29-31; 37, (2009/03/07)
Provided herein are compounds, compositions and methods for decreasing NFkB DNA-binding activity in a patient comprising administering of a therapeutically effective amount of a compound or composition of the application to the patient to reduce, alleviate or treat various gastrointestinal diseases, such as inflammatory bowel disease (IBD).